THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Raid Aljumaily to Antineoplastic Agents, Immunological

This is a "connection" page, showing publications Raid Aljumaily has written about Antineoplastic Agents, Immunological.
  1. Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
    View in: PubMed
    Score: 0.601
  2. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
    View in: PubMed
    Score: 0.177
  3. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 05; 155:151-155.
    View in: PubMed
    Score: 0.177
  4. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
    View in: PubMed
    Score: 0.160
  5. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.
    View in: PubMed
    Score: 0.150
  6. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018 01; 19(1):51-64.
    View in: PubMed
    Score: 0.141
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES